Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Change in Accured Expenses: 2009-2024

Historic Change in Accured Expenses for Assembly Biosciences (ASMB) over the last 16 years, with Dec 2024 value amounting to $1.4 million.

  • Assembly Biosciences' Change in Accured Expenses rose 97.03% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year increase of 478.87%. This contributed to the annual value of $1.4 million for FY2024, which is 162.05% up from last year.
  • Assembly Biosciences' Change in Accured Expenses amounted to $1.4 million in FY2024, which was up 162.05% from -$2.2 million recorded in FY2023.
  • Assembly Biosciences' Change in Accured Expenses' 5-year high stood at $3.8 million during FY2020, with a 5-year trough of -$5.1 million in FY2021.
  • Its 3-year average for Change in Accured Expenses is -$130,333, with a median of $458,000 in 2022.
  • As far as peak fluctuations go, Assembly Biosciences' Change in Accured Expenses plummeted by 588.43% in 2023, and later skyrocketed by 162.05% in 2024.
  • Yearly analysis of 5 years shows Assembly Biosciences' Change in Accured Expenses stood at $3.8 million in 2020, then tumbled by 232.34% to -$5.1 million in 2021, then spiked by 109.03% to $458,000 in 2022, then plummeted by 588.43% to -$2.2 million in 2023, then surged by 162.05% to $1.4 million in 2024.